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EFFECTS OF ADOPTIVE TRANSFER OF OSP A-SPECIFIC TH2 T 
CELLS ON THE EVOLUTION OF LYME BORRELIOSIS IN MICE. Paul 
H. Lee and Iinda K. Bockenstedt. Section of Rheumatology, Department of 
Internal Medicine, Yale University, School of Medicine, New Haven, CT. 
In many infectious diseases, the dominating effects of Thl or Th2 T cell 
responses elicited by the pathogen in the host significantly alters the course 
of disease. In general, Thl cells promote cell-mediated immunity whereas Th2 
cells augment antibody production. Because specific antibody is important in 
prevention of Borrclia burgdorferi infection, it is surprising that only Thl- 
type T cells have been isolated from patients with chronic Lyme disease. We 
propose that the presence of Borrelia-specific Th2 cells may alter the course of 
Lyme borreliosis in mice. Dr. Bockenstedt's laboratory has previously defined 
a T cell epitope on the outer surface protein (Osp) A of Borrelia burgdorferi, 
strain N40, which elicits a Th2 response after immunization of C3H mice. In 
adoptive transfer experiments using T cells derived from mice immunized with 
the Osp A peptide or a control antigen (ovalbumin), we examined the effects of 
Osp A-specific Th2 cells at three critical stages of Borrelia burgdorferi 
infection: establishment of infection, disease evolution, and disease 
regression. The results suggest that while these cells appeared to have no 
effect during the initial phase of infection, Osp A-specific Th2 cells can 
attenuate the severity of arthritis during the disease regression phase. The 
accelerated disease regression occurred in the absence of specific antibody to 
Osp A. Possible mechanisms by which Th2 cells mediated their effects in early 




Lyme borreliosis is a tick-transmitted, multi-organ system disease 
caused by the spirochete Borrelia burgdorferi. Since the initial description 
in 1977 (1), Lyme borreliosis has become the most common vector-borne 
infection in the U.S and is a major public health concern (2). In most 
endemic areas of the Northeast, a significant percentage of the population 
have had clinical manifestations attributed to Lyme borreliosis. During 
the 1980's in Ipswich, Massachusetts, 35% of 190 residents living near a 
nature preserve had symptoms of Lyme borreliosis (3). In Fire Island, N.Y., 
7.5% of the population had evidence of infection in a 5 year study (4). 
The major endemic areas of B burgdorferi in nature are the Northeast, 
Upper Midwest and West Coast states. This spread of disease as well as the 
concern over possible development of late, unremitting sequelae in 
patients who are not promptly treated has led to intense investigation into 
the early diagnosis and prevention of this disease. The investigation of the 
host immune response to Borrelia burgdorferi and spirochete evasion of 
host immunity has led to an experimental vaccine (5). 
Clinical Manifestations in Humans. 
The clinical manifestations of Lyme borreliosis can be described in 
three stages, similar to the staging system used in other spirochetal 
infections (e.g. syphilis) (6, 7). 
Stage I (localized erythema migrans). Initially, the spirochetes are 
transmitted by the Ixode tick to the skin where 60-80% of Lyme borreliosis 
patients develop erythema migrans (EM) - often accompanied by fever 
and local lymphadenopathy. EM is the most specific manifestation of 
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Lyme borreliosis (1). 
Stage II (disseminated infection). From days to weeks, the 
spirochetes disseminate via the bloodstream from the skin to all organs 
including heart, joints, and nervous system (8). During this stage, patients 
often have episodic manifestations of disease involving these organs but 
very little permanent or irreversible damage. Clinical signs include 
multiple annular skin lesions, migratory muscle pain, and brief attacks of 
oligoarticular arthritis. About 8% of patients have fluctuating 
atrioventricular blocks (9) and 20% of the patients develop 
meningoencephalitis, cranial neuritis, or peripheral radiculoneuropathy 
(10). Surprisingly, during this stage, spirochetes are few in number (11, 
12) but elicit a vigorous immune response (6, 13). This observation has 
led to the assumption that it is the host immune response rather than the 
spirochete itself that leads to tissue damage and disease. Despite the 
intense immune reaction to infection, the spirochetes appear somehow to 
avoid elimination by the host. In fact, the immune response eventually 
becomes quiescent despite persistence of organism in tissues. 
Stage III (chronic disease). After episodic manifestations of 
infection, some patients develop chronic, unremitting disease, particularly 
involving the joints or nervous system (14, 15). At this stage, irreversible 
damage may occur, resulting in permanent disability. Although the 
presence of spirochetes is thought to be driving the immune response even 
at this stage of infection, the propensity towards chronic disease may also 
be genetically linked to certain HLA haplotypes (15). 
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Host Defenses Against Borrelia Burgdorferi 
Borrelia burgdorferi is a spirochete, similar to other Borrelia species 
in DNA homology and structure (16). It has an outer cell membrane 
containing many outer surface proteins (Osp) - important in host 
protective immunity (17, 18, 19). The abundant 31kDa Osp A and 34kDa 
Osp B comprise most of the outer membrane proteins in cultured North 
American organisms (20, 21). Beneath the outer layer, in the periplasmic 
space, is the 41kDa flagellin protein, necessary for motility (16). 
In addition to Osps, other immunogenic proteins of the spirochete 
have been identified using infected human and animal sera. These include 
heat shock proteins, a 39KDa protein (p39) and 22kD proteins including 
Osp C (22, 23). 
In patients with Lyme borreliosis, an IgM response develops first to 
flagellin, 3-6 weeks after infection, followed by IgG isotype switching (24). 
An early immune response has also been shown for 39kDa and 22kDa (Osp 
C) proteins. Chronic Lyme disease patients often develop a widening 
response to many other Borrelia burgdorferi proteins later in the course of 
the disease, including 60, 70, 83, 93 kDa proteins (22). Only a few 
patients, generally those with chronic disease, develop antibodies to Osps 
A and B (22). Furthermore, these Osp A and B antibodies arising in late 
disease are not capable of eradicating the spirochetes from infected 
patients. In contrast, sera (from patients with chronic disease) which 
contain Osp A and B antibodies have been shown to confer at least partial 





Many animal models of Lyme borreliosis have been developed which 
can reproduce some of the pathology observed in human disease. The 
inbred weanling C3H/HeJ mouse is a particularly useful model for study of 
this disease because it has an intact, well-characterized immune system 
and reproducibly develops a syndrome resembling human Lyme disease 
within 2 weeks of Borrelia burgdorferi infection (26). N40 spirochetes 
inoculated into the skin of these mice disseminate via the blood to every 
organ, although disease is generally confined to heart and joints. Blood 
and spleen cultures are positive for Borrelia starting 3 days after 
intradermal inoculation and inflammation of the heart and joints appears 
by 7-10 days. The spirochetes are no longer detectable within the blood 
around 21 days after infection, a time coinciding with the onset of 
regression of carditis and arthritis. A subset of infected mice have 
recurrent spirochetemia and arthritis many months after infection, 
although arthritis tends to be milder and affects fewer joints (27). No 
immunocompetent animal model to date develops chronic unremitting 
disease similar to that found in patients, nor do mice develop neurologic 
disease. 
The humoral immune response arising during experimental murine 
borreliosis parallels that seen in humans. Mice inoculated with less than 
1C)4 spirochetes seroconvert readily to flagellin, p39, and 22kDa proteins 




The Role of Cellular Immune Response 
Several theories have been introduced to explain this apparent lack 
of early response to Osps A and B in humans and mice (22): the Osp may 
be masked by host components which prevent an immune response until 
late in the illness (28), much like Schistosomula eggs, coated with host 
proteins, are not antigenic until they break open or die. Alternatively, 
Osps may undergo antigenic variation as in Borrelia hermsii (29) or be 
downregulated. A third possible explanation for the apparent lack of 
antibody response to Osps A and B is that the type of T cell response 
elicited by B. burgderfori early in infection favors cell-mediated over 
antibody -mediated effects. Similar to many diseases which have variable 
clinical presentations, specific T cell subtype (Thl vs Th2) expression may 
retard the appearance of early borrelicidal antibodies to Osps A and B, 
thereby attenuating early, specific immune clearance of Borrelia 
burgdorferi. Thus, cell-mediated immunity may provide one explanation 
for the lack of an early antibody response to abundant protective proteins. 
The cellular immune response, however, has been poorly 
characterized. Most of the investigations in humans of the cellular 
immune response have used peripheral blood mononuclear cells (PBMC) 
instead of specific or enriched T cells as representing cellular immune 
response. Also, whole spirochete or spirochetal lysates, which contain B 
cell mitogens, have often been used to stimulate this response. Therefore, 
proliferative response may be due to cell types other than specific T cells. 
With these limitations in mind, however, many patients have been shown 
to develop early and strong cellular immune reactivity to Borrelia 
burgdorferi (30, 31, 32). PBMC response increases above control 2-3 
weeks postinfection with Borrelia burgdorferi (33). Patients with chronic 
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Lyme arthritis have a greater response to spirochetal antigens than those 
who resolve their disease. Treatment also appears to cause a concomitant 
decline in the response of PBMC, corresponding with clinical disease 
regression (31). A more specific investigation of the T cell response to 
recombinant Osp A has shown an elevated T cell response in early Lyme 
borreliosis, compared to healthy control patients (35, 36, 37). 
Characterization of Osp A-specific T cells has shown only Thl-type cells, 
suggesting that a preferential expression of a Thl response in patients may 
prevent sufficient, potentially borrelicidal antibody response against the 
Osps. 
The Effects of Thl vs Th2 T-Cell Response in Other Diseases 
Models of preferential expansion of a specific Th phenotype are 
found in many diseases, including leprosy, leishmania, and syphilis. The 
dominance of one Th response over another appears to cause vastly 
different disease progression and prognosis in patients and in animal 
models of these diseases. The understanding of the cell-mediated immune 
response in these diseases may help elucidate the lack of early antibody 
response to protective outer surface proteins in Lyme borreliosis. 
In mice, there are two subsets of CD4+ helper T cells (38). Thl 
subset of T cells is important in induction of delayed type hypersensitivity 
(DTH), recruitment of macrophages, and host response to local and 
intracellular pathogens (39). These actions are in part mediated by the T 
cell secretion of a select repertoire of cytokines: interleukin 2 (IL-2), 
gamma-interferon (IFN-y), and tumor necrosis factor beta (TNF-£) (38). 
The Th2 T cell response is important as a helper function for Ig synthesis. 
This subset of T cells is needed to produce a high and persistent antibody 
. 
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production of IgM, IgG, IgA, and IgE and is needed for activation and 
prolonged survival of eosinophils and mast cells. Th2 T cells secrete 
interleukin 4 (IL-4), IL-5, IL-6, IL-10 (38, 40). A third subset of T cells 
called ThO secretes IL-2, IFN-g, IL-4, and IL-5 and is believed to be the 
pluripotent precursor cell subset to both Thl and Th2 T helper cells (41). 
The murine immune system can switch from a predominant 
response of one subset of T cells to another or recruit ThO cells into a Thl 
or Th2 response (42). This switch or recruitment of T cells is based in part 
on the cytokine milieu predominating in the immune response. IFN-y 
(produced by Thl cells) promotes maturation of Thl cells, activates 
macrophages, and stimulates natural killer (NK) cells, while inhibiting Th2 
cell proliferation and IL-4 production (43). IL-4 (produced by Th2 cells) 
potentiates proliferation and cytokine synthesis of Th2 cells. In fact, low 
levels of IFN-g and high levels of IL-4 can cause a Th2 cell predominant 
response (44). High levels of IFN-y can promote differentiation of 
precursor cells into Thl cells in vitro (45) and in murine models of 
Leishmania (46). 
In humans, healthy donor CD4+ clones have mostly an unrestricted 
cytokine profile, resembling the murine ThO cells. T cell subsets with 
different cytokine secreting profiles are also found in human disease states 
(47). Human T cell clones specific for Borrelia burgdorferi are able to 
secrete IL-2 and IFN-y but not IL-4 or IL-5. In fact, as in mice, the Thl 
response appears to be directed at viruses and mostly intracellular 
bacteria while the Th2 cell response is directed towards allergens and 
parasitic infections. These responses correlate with cytokine profiles and 
action of Th cells. 
The subset of T cells activated in some diseases have a significant 
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effect on the type of resulting pathology, clinical presentation, and often 
mortality in patients with the disease and in murine models. One of the 
most dramatic differences in disease states (due to differential T cell 
response) occurs in Hansen’s Disease (48), caused by infection with 
mycobacterium leprae. Tuberculoid leprosy is a form of this disease which 
is slowly progressing with large numbers of lymphocytes, epithelioid and 
giant cell granulomas and very few acid-fast bacilli. In contrast, the 
lepromatous form of leprosy is a rapidly progressing disease with 
significant parasitization of macrophages and Schwann cells and few T 
cells and plasma cells in tissue. The difference in these forms of the same 
disease appears to be the host immune response. The milder tuberculoid 
form has a Thl-like response with IL-2 and IFN-y expressed by the T cells 
while the severe lepromatous form has a Th2 like response, expressing IL-4 
and IL-5. (49) 
A similar effect is observed in murine models of Leishmania major 
infection. In BALB/c mice, the predominant response to infection is a Th2- 
like cytokine pattern with high levels of IL-4 and IL-5 but little IFN-y (46). 
These mice have poor delayed-type hypersensitivity even with high 
antibody titers and go on to develop localized lesions, parasite replication, 
visceral disease and, finally, succumb to the disease. On the other hand, 
C57/B1/6 mice develop a Thl-like response to Leishmania infection with 
high levels of IFN-y and little IL-4 or IL-5 (50). This Thl-like response is 
associated with strong DTH, low antibody titers, and disease regression. 
T cell subset response and disease progression, in fact, can be 
controlled by providing specific cytokines. Mouse strains which normally 
have Thl response to infection with Leishmania revert to a strong Th2 
response with disease progression when given a single dose of anti-IFN-y 
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(51). Giving a single dose of IFN-y to BALB/c mice early in infection, 
causes a Thl like response rather than a Th2 in these mice (52). 
Extracellular parasites, trypanosoma, and schistosoma also display a 
Thl and Th2 subset-dependent disease progression. Th2 response 
depresses Thl response and leads to chronic infection in both of these 
diseases(53). Also, Treponema pallidum, a spirochete and causative 
organism of syphilis, induces variable disease progression based on the 
level of delayed-type hypersensitivity (DTH) (53). Syphilis is particularly 
interesting as a comparative disease to Lyme borreliosis because of the 
similarity in the latency and chronic course of disease and because of 
evidence of T cell subset dependent response to a spirochetal and 
nonintracellular organism. It is postulated that those patients who 
develop tertiary syphilis have a weak DTH or Thl response while those 
who undergo disease regression without long-term infection have a strong 
DTH reaction (54). In a rabbit model of syphilis, early Thl-like response 
were down regulated 9-14 days after infection while the Th2 response 
remained elevated up to 90 days after infection.(53). 
Although in leishmania, leprosy, and other diseases including 
syphilis the Thl response to the pathogen appears to lead to disease 
regression or to a slowly progressing form of the disease, the opposite may 
be true in Lyme borreliosis. Antibody is known to be the most important 
factor in disease prevention, and only a Thl T cell response (not Th2) has 
been found in diseased patients - even those that are chronically infected 
with B burgderfori. This finding is striking since a Th2-type response is 





We propose that Osp-specific Th2 T cells may alter the course of 
Lyme borreliosis in mice. This knowledge may be valuable in explaining 
the apparent lack of early antibody response to abundant Osps in patients 
with Lyme borreliosis. These patients all appear to express Thl phenotype 
after infection with Borrelia spirochetes. The lack of a Th2 response to the 
Borrelia spirochetes may thwart the host immune system's attempt to 
mount a sufficient and specific antibody response to the outer surface 
proteins. 
Th2 cells can secrete cytokines that result in a dominance of Th2 
over Thl cell maturation. Dr. Bockenstedt has recently found a synthetic 
peptide spanning amino acid 179-193 of Osp A can elicit an Osp A-specific 
Th2 response in mice. This study examines the effects of adoptively 
transferred Osp A peptide primed Th2 cells on the onset, progression and 
regression of Lyme borreliosis in mice. 
Experimental Design: Overview 
Th2-type T cells were primed in 6-8 week old C3H/HeJ mice by 
immunization with Osp A peptide 179-193 in complete Freund's adjuvant 
(CFA). Ten days later, immunized T cells were isolated from regional 
lymph nodes and spleen and adoptively transferred into mice at 3 stages 
of infection: 1) immediately prior to inoculation with Borrelia burgdorferi, 
2) after infection was established during disease evolution, and 3) during 
disease regression. We then sacrificed the mice to assess the pathology in 
the hearts and joints, to examine for spirochete by cultures of various 
organs, and to assess Osp A antibody response to the spirochete in a Th2 
phenotype by immunoblots.. 
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Materials and Methods 
Mice 
Weanling and 6-8 weeks old female C3H/HeJ mice were purchased from 
Jackson Laboratory (Bar Harbor, ME) and housed in filter-top cages. Food 
and water were provided ad libitum. The mice were killed with carbon 
dioxide gas. 
Borrelia burgdorferi 
A cloned N40 strain of B. burgdorferi with proven infectivity and 
pathogenicity in C3H/HeJ mice was used. The spirochetes were grown in 
modified Barbour-Stoenner-Kelly (BSK II) medium (55) at 33° C. 
Spirochetes were inoculated after the third in vitro passage at log-phase of 
growth and after dilution to 10^ Borrelia/ml with BSK II medium. 
Culture Media 
Click's media supplemented with 1% penicillin, 1% gentamicin, 1% L- 
glutamine, 5x10"^ M 2ME (Sigma), and 5% FCS was used for cell cultures. 
Derivation and characterization of T cells 
The synthetic Osp A peptide 179-193 and ovalbumin were provided by Dr. 
Linda Bockenstedt. Ovalbumin-specific T cells were derived and 
characterized in the same way as the Osp A specific T cells. Osp A peptide- 
specific T cells were generated from C3H mice immunized with 50ug of 
peptide emulsified in CFA. Six to eight days after injection of peptide to 
peritoneum, foot pad, and base of tail of each mouse, the spleen and 
regional draining lymph nodes were aseptically collected. Lymph nodes 
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and spleens of one or several mice were combined and made into a single 
cell suspension. After erythrocytes were lysed, the remaining cells were 
incubated overnight (5% C02, 37° C) with lOug/ml of specific peptide. 
Expanded T cells were enriched over a nylon wool column and used for 
adoptive transfer. 
Prior to nylon wool enrichment, 5x10^ peptide-primed cells were 
placed into wells of 96-well microtiter plate to characterize the cells. To 
each set of duplicate wells, recombinant Osp A (rOsp A) at different 
concentrations (lOOug/ml, lOug/ml, lug/ml), ovalbumin (lOOug/ml), 
PPD (lOug/lOul), and media only were added. The cells were incubated 
for 4 days (5% CO2, 37° C), then pulsed with luCi [^H]-thymidine/well 
overnight and harvested. [^H]-thymidine incorporation was assessed 
using a Beckman Beta-plate scintillation counter. 
Prior to pulsing with thymidine, 50ul of supernatant from each well 
was transferred to another 96-well microtiter plate to assess cytokine 
secretion of the cell. The IL-4 dependent CT.4S cell line (5x10-3 cells/well) 
was added to each supernatant and incubated (5% CO2, 37° C) for 24hrs. 
These cells were then pulsed with [-^HJ-thymidine (Amershan) and 
incubated overnight and harvested. The thymidine incorporation was 
assessed using a Beckman Beta-plate scintillation counter. 
Immunoblot 
Borrelia burgdorferi N40 lysate and recombinant Osp A and C antigens 
prepared by Dr. Linda Bockenstedt were electrophoresed on 1 2% SDS- 
PAGE polyacrylamide minigel. The proteins were transferred to 
nitrocellulose sheets and stained with Ponceau Red (0.1% Ponceau S in 1% 
acetic acid) to confirm transfer. After destaining with dd H2O, the 
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nitrocellulose sheets were blocked for lhr in 5% nonfat milk in PBS. 
Antigen strips were incubated with test sera diluted 1:100 at room 
temperature for lhr. The strips were washed three times in PBS with 
0.05% Tween 20 (PBST), then incubated for 1 hr. with alkaline 
phosphatase-labeled goat anti-mouse immunoglobulin diluted 1:5000 in 
PBST. After washing three times with PBST, the strips were developed with 
BCIP system with nitroblue-tetrazolium (One Component system, 
Kirkegaard and Perry Laboratories). 
Experimental plan 
C3H mice were divided into three groups each containing 10 mice: 5 
receiving Osp A-specific T cells and 5 receiving ovalbumin-specific T cells. 
All mice were inoculated subcutaneously with 10^ N40 Borrelia 
burgdorferi in 0.1ml BSK II medium at set time intervals from the T cell 
transfers. Group I mice were inoculated with B. burgdorferi and injected 
with T cells on Day 1 and sacrificed 14 days later. Group II mice were 
inoculated with B burgdorferi on Day 1, received adoptive transfer of T 
cells 3 and 10 days later, and were sacrificed 14 days after spirochete 
inoculation. Group III mice were inoculated on Day 1, received adoptive 
transfer of T cells 14 and 21 days later, and were sacrificed 30 days after 
inoculation with spirochetes. The adoptive transfer of T cells into mice 
were done by two methods: subcutaneous and retro-orbital injections. 
Some groups of mice received subcutaneous injection of 1x10^ to 7x10^ T 
cells in 0.1ml PBS on the back (on a site opposite to the B. burgdorferi 
inoculation). Mice receiving retro-orbital injections were anesthetized 
with methoxyflurane. The number of Osp A-specific and ovalbumin- 
specific T cells used in the T cell transfers were the same in each group of 
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mice and ranged from 1-7 x 10^ T cells depending on the experiment. 
Histology and tissue cultures 
All cultures and histopathology were done by Dr. Stephen Barthold's 
laboratory. Blood, ear punch (1.5 mm diameter), and urinary bladder 
specimens were aseptically collected from each mouse for culture. Two 
drops of blood were placed directly into 8-ml glass screw top tubes 
containing 7ml of modified BSK II medium without antibiotics. Duplicate 
ear punches were also collected and cultured with or without Ciprofloxacin 
(which does not kill the spirochete). Bladder was cultured similarly. The 
spleen was aseptically collected and homogenized in 4x volume of BSK II 
medium. Then, 0.5ml of homogenate was placed in a glass screw top tube 
containing 7 ml BSK medium and cultured. All cultures were incubated 
for 2 weeks after which the presence of viable spirochetes was confirmed 
by darkfield microscopy. 
The heart and tibiotarsal and knee joints were also collected and 
examined for histopathology. These tissues were immersion-fixed in 10% 
neutral buffered formalin, pH 7.2. Decalcifying solution (Baxter Health 
Corp., McGaw Park, IL) was used to demineralize bone in joints. Tissues 
were embedded in paraffin, sectioned by standard technique, and stained 
with hematoxylin and eosin then examined for inflammation and 
pathology. Examiners were blinded to experimental group, and the 
severity of inflammation were recorded as (-) for no inflammation to (+++) 
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Because only Thl phenotype cells are found in B burgdorferi 
infection, we adoptively transferred Osp A specific and control Th2 cells 
into mice to determine the effects of these cells on T cell dependent 
antibody production and the onset, progression, or regression of Lyme 
borreliosis in mice. Group I mice received T cells on the day of spirochete 
inoculation, Group II mice received T cells after infection was established 
and during the evolution of arthritis and carditis (3 and 10 days after 
infection), and Group III mice received T cells during disease regression 
(14 and 21 days after infection). Identical numbers of ovalbumin-primed 
T cells Osp A-primed T cells were used in all transfers. Evidence of change 
in disease onset, progression, or regression were assessed by cultures of 
blood, bladder, spleen, and ear and histologic examination of the heart 
and knee and tibiotarsal joints. 
T cells used in adoptive transfer experiments were analyzed for 
antigen specificity and cytokine secretion. The transferred cells all had 
much greater proliferation with the presence of specific peptide compared 
with nonspecific peptide or no peptide, particularly in T cells incubated in 
lOOug/ml (Figures 1-6). Furthermore, all the Osp A-primed T cells had a 
dose-dependent proliferation to their specific antigen. The ovalbumin- 
primed T cells did not appear to have a dose-dependent response to 
specific peptide concentrations. These cells mainly had strong specific 
proliferative response to lOOug/ml concentration of recombinant 
ovalbumin. All cells had Th2 phenotype with production of IL-4. The IL-4 
production of cells was quantified using the proliferation of the IL-4 
dependent murine T cell line CT.4S. Therefore, the cells transferred into 
. 
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experimental mice were specific for the Osp A or ovalbumin and had 
either an effector ThO or Th2 phenotype. 

Page 20 
Fig. 1: Group I - Assay for IL-4 production by transferred T cells. 
Osp A Ovalbumin 
Fig. 1-6: Osp A or Ovalbumin-primed T cells used for adoptive transfer were incubated 
in specific peptide at concentrations of 100, 10, lug/ml ("Specific 100", "Specific 10," 
"Specific 1"). In the Osp A-primed T cell assay, ovalbumin at lOOug/ml was used for 
"nonspecific" response. Osp A at lOOug/ml was used for "nonspecific" response in 
the ovalbumin-primed T cell assays. The response of T cells in PPD was used to assess 
the success of immunization ( "+ control") and the response of T cells in media alone 
was used as "- control." The supernatant from the proliferation assays were analyzed 
for IL-4 by thymidine incorporation of IL-4 dependent murine T cell line. The 
results are duplicated and the mean of the dose dependent IL-4 production of T cells 
are given above as counts per minute (CPM). 
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Fig. 3: Group II, Second transfer - Assay for IL-4 production by transferred T cells. 
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Fig. 4: Group II (Repeat), Second transfer - Assay for IL-4 production by transferred 
T cells. 
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Fig. 6: Group III, Second transfer - Assay for IL-4 production by transferred T cells 
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In the first Group I experiment, the blood and organ cultures from 
mice showed significant differences in isolation of spirochetes between 
mice receiving Osp A T cells and control T cells (Table 1). This group of 
mice were injected subcutaneously on the back with purified T cells from 
immunized mice. The five mice that received ovalbumin-primed T cells all 
had spirochete infected organs. However, only 2 of the 5 mice injected 
with Osp A-primed T cells had any infected organ. The number of mice 
with carditis also paralleled the culture results. The severity index for 
arthritis, however, was similar in both sets of mice. One mouse in the Osp 
A set had completely negative culture or histology results. Two of the five 
mice in the Osp A set clearly had arthritic disease but no spirochetes in the 
other organs and no carditis. Based on these limited number of mice, it 
appears that the spread of spirochetes to organs and inflammation of the 
heart was attenuated in mice receiving Osp A peptide primed T cells. 
The Group I study was repeated using Osp A peptide and 
ovalbumin-primed T cell clones, injected retro-orbitally into mice. In this 
repeat study, all mice of both Osp A and control sets had multi-organ 
presence of spirochetes by culture. The Th2 T cells did not appear to 
attenuate or affect the spread of spirochetes in the repeat experiment. 
The histology of the repeat study showed that mice receiving Osp A- 
primed cells appeared to have slightly more severe joint disease (severity 
index, Osp A vs ovalbumin mice: 2.6 vs 1.8, P < 0.025) but the same degree 
of carditis (Table 2). 
In Group II mice, purified T cells from immunized mice were 
transferred (by subcutaneous back injection) after spirochete 
dissemination and before regression of disease. The cell transfer was 
repeated 1 week later to ensure continued presence of Th2 cells. Again, 
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the study was repeated in similar experimental conditions, using greater 
number of purified T cells transferred retro-orbitally. One mouse in the 
repeat study died during the injection of T cells and was excluded from 
the analysis. No significant difference in the severity of arthritis (Index, 
ovalbumin vs Osp A: 1.9 vs 2.6 (P > 0.10) and 1.7 vs. 1.5 (P > .25)) and 
carditis and the presence of spirochetes in organs could be appreciated 
between the Osp A and ovalbumin-primed mice in both the experiments of 
Group II (Table 3 and 4). 
The third group of mice were injected retro-orbitally with purified T 
cells from immunized mice during the third and fourth week of infection - 
at the time of disease regression. In these mice, there was a significant 
difference in the severity of disease with appreciable attenuation of 
arthritis (severity index, ovalbumin vs. Osp A: 3.0 vs. 1.8 (P=0.005)) and 
carditis in the mice receiving Osp A primed T cells (Table 5). Of the five 
mice with Osp A primed T cells, only three had carditis, while the other 
two had only trace or mild disease. In the mice which received ovalbumin- 




The effects of Osp A and ovalbumin-primed T cells on the presence of 
spirochetes and degree of arthritis and carditis in infected mice. 
Group I Cultures Arthritis Carditis 
Oval micel Pos 0 Pos 
2 Pos 0 Mild Pos 
3 Pos 2 Pos 
4 Pos 1 Pos 
5 Pos 1 Pos 
Average of 5/5 0.8 5/5 
oval mice (SD 0.8) 
Osp A 1 Neg 0 Neg 
2 Pos 3 Pos 
3 Neg 1 Neg 
4 Neg 2 Neg 
5 Pos 2 Pos 
Average of 2/5 1.6 2/5 
Osp A mice (SD 1.0) 
Individual mice were considered positive (Pos.) if spirochetes could be grown 
from any of the cultured organs (blood, spleen, ear, or bladder). The disease 
severity index for arthritis was calculated by adding the severity (designated 
from - to +++) in the most inflammed tibiotarsal joint. The index average and 




GrouD I Cultures Arthritis Carditis 
Repeat 
Oval 1 Pos 2 Pos 
2 Pos 1 Pos 
3 Pos 2 Pos 
4 Pos 2 Pos 
5 Pos 2 Pos 
Average of 5/5 1.8 5/5 
oval mice (SD 0.5) 
Osp A 1 Pos 2 Pos 
2 Pos 2 Pos 
3 Pos 3 Pos 
4 Pos 3 Pos 
5 Pos 3 Pos 
Average of 5/5 2.6 5/5 




Group II Cultures Arthritis Carditis 
Oval 1 Neg 0 Neg 
2 Pos 2.5 Pos 
3 Pos 3 Pos 
4 Pos 2 Pos 
5 Pos 2 Pos 
Average of 4/5 1.9 4/5 
oval mice (SD 1) 
Osp A 1 Pos 3 Pos 
2 Pos 2 Pos 
3 Pos 3 Pos 
4 Pos 2 Pos 
5 Pos 3 Pos 
Average of 5/5 2.6 5/5 




Group II Cultures Arthritis Carditis 
Reoeat 
Oval 1 Pos 2 Pos 
2 Pos 2 Pos 
3 Pos 0.5 Pos 
4 Pos 2 Pos 
5 Pos 2 Pos 
Average of 5/5 1.7 5/5 
oval mice (SD 0.7) 
Osp A 1 Pos 2 Pos 
2 Pos 2 Pos 
3 Pos 1 Pos 
4 Pos 1 Pos 
Average of 4/4 1.5 4/4 




GrouD III Cultures Arthritis Carditis 
Oval 1 Pos 3 Pos 
2 Pos 3 Pos 
3 Pos 3 Pos 
4 Pos 3 Pos 
5 Pos 3 Pos 
Average of 5/5 3 5/5 
oval mice (SD 0) 
Osp A 1 Pos 2 Pos 
2 Pos 1 Mild Pos 
3 Neg 1 Trace 
4 Pos 2 Pos 
5 Pos 3 Pos 
Average of 4/5 1.8 3.5/5 
Osp A mice (SD 0.8) 
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Sera obtained at the time of sacrifice were tested by immunoblots of 
recombinant Osp A and C (not shown) and N40 spirochete lysate for 
antibodies to B burgdorferi. None of the mice appear to have IgG antibody 
response to Osp A during the first few weeks of infection. However, almost 
all the mice developed IgG antibodies to 22kDa Osp C, P39 and 41kDa 
flagellin (Figures 7-11). Group II ovalbumin mice also developed 
antibodies to a protein in the 41-43kDa range (Figure 9). Only one of the 
Group II Osp A mice developed this antibody. Most of the Group III mice 
had widening antibody response to low molecular weight proteins and to a 
protein in the 41-43kDa range (Figure 11). All the mice which had no 
culture or histopathologic evidence of infection also had no antibody 
response detected against B. burgdorferi antigens. One mouse in the Osp 
A Group I with very mild arthritis also had no antibodies specific for 
Borrelia. The transfer of Osp A-specific T cells did not appear to alter 
significantly the antibody response when compared to the antibody profile 
in mice receiving ovalbumin-specific T cells. 
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Figures 7-11. IgG Immunoblot of B. burgdorferi N40 lysates using mice sera 
diluted at 1/100. The number in the lane corresponds to the mouse numbered 
in Tables 1 -5. 
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The T cell immune response to Borrelia burgdorferi infection in 
mice has been the focus of recent efforts into understanding the 
adaptation of this spirochete to the mammalian host. The finding of 
enhanced production of gamma-interferon (a cytokine produced by Thl 
cells) (36,37) and the presence of activated macrophages in B. burgdorferi 
infected mice supports a bias in the differentiated T helper cell repertoire 
towardscell-mediated immune responses. More direct evidence comes 
from characterization of T cell lines isolated from the synovium of patients 
with Lyme arthritis, in which only those T cells that secrete a cytokine 
profile produced by Thl cells (and not Th2 cells) are found (37). 
Osp A antibodies can protect naive mice from challenge infection. 
Yet, these antibodies do not arise until quite late, if at all, during 
experimental and natural infection, despite the dominance of Osp A on 
spirochetes examined in culture and in ticks (27). We hypothesized that 
the lack of early Osp A antibody production in infected mice was, in part, 
due to the type of Th cell response elicited during infection. Recently, Dr. 
Bockenstedt's laboratory has produced T cell hybridomas from splenocytes 
of C3H mice sacrificed at day 14 of infection. Some of these T cell hybrids 
proliferate in response to Osp A and secrete both IL-2 and gamma- 
interferon, consistent with a Thl phenotype. Therefore, immunologic 
exposure to Osp A occurs early in infection even though specific 
antibodies cannot be detected, and such exposure elicits a Thl-type T cell 
response. Although Thl cells can promote IgGl and IgG3 antibodies, this 
Thl response does not appear to lead to early seroconversion to Osp A. 
Dr. Bockenstedt has also identified a T cell epitope on Osp A which induces 
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differentiation of T cells from C3H mice into Th2-type cells after 
immunization with the peptide in CFA. Mice primed with the Osp A T cell 
epitope, then infected with low-dose spirochetes (10^) can seroconvert to 
Osp A within the first 2 weeks of infection. The purpose of this study was 
to determine if primed Th2 T cells transferred at different stages of early 
infection in C3H mice could affect the antibody response to Osp A and/or 
course of disease. 
The preliminary experiment in which mice received ovalbumin 
(Ova) or Osp A primed Th2 cells at the time of infection was suggestive 
that Osp A specific T cells may have an effect on the early evolution of 
disease. Whereas 5/5 mice receiving Ova-specific T cells were infected and 
had disease, 4/5 mice in the Osp A group were infected and only 3/5 mice 
had significant disease. A second experiment failed to confirm this finding 
and even suggested that Osp A T cells may increase the degree of arthritis 
(several index of 2.6 vs 1.8 (P < 0.025)). The difference between the two 
experiments was that in the second, Th2 cell lines had been established in 
culture and likely consisted of a completely differentiated Th2 population. 
The first experiment (and all other experiments in this study) were 
performed using purified T cells from mice immunized with either Osp A 
or ovalbumin. These T cells secreted IL-4 in response to the specific 
antigen, but likely contained both undifferentiated ThO as well as 
differentiated Th2-type cells. It has been suggested that Osp A specific T 
cells can actually enhance arthritis in humans, based on the finding that 
Lyme disease patients with chronic arthritis have a greater prevalence of 
Osp A specific T cells (56). 
Studies of T helper cell differentiation suggest that naive T helper 
cells develop into effector ThO cells when primed with antigen (42). It is 
.* 
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from this unrestricted ThO cell population (which secrete IL-2, gamma- 
interferon, and IL-4) that Thl and Th2 cells arise upon restimulation with 
antigen in the presence of cytokines (57). In murine leishmaniasis, IFN- 
gamma given prior to infection causes CD4+ T cells to differentiate into 
Thl phenotype cells, while IL-4 promoted a Th2 phenotype (45, 46). The 
effect of the cytokine environment is critical to maintenance of Th cell 
phenotype. It has been demonstrated that the ThO and Thl phenotypes 
are relatively unstable, with Thl cells incubated in the presence of IL-4 
converting to a Th2 phenotype. In contrast, the Th2 phenotype does not 
appear to readily convert to a Thl, no matter what the cytokine 
environment (58). In our study, the assays for cytokine secretion of T 
cells detected the presence of IL-4 which can be produced by both Th2 and 
ThO cells. Therefore, the cells used in the transfer may have had 
significant numbers of undifferentiated ThO effector cells. The effects of 
the dominant Thl response in early infection likely produced a cytokine 
environment rich in IL-2 and gamma-interferon. When the T cells were 
then transferred into this environment, the ThO cells could differentiate 
into a Thl phenotype. Adoptively transferring a population of cells which 
contain Osp A specific ThO cells may therefore enhance the arthritis if they 
differentiate, because of the cytokine environment existing in early 
infection, into Thl-type cells. The effect appears to be antigen specific as 
we did not see similar exacerbation of arthritis in mice receiving Ova- 
specific T cells. We did not attempt in these studies to reisolate T cell lines 
from mice to determine the relative prevalence of Th2 vs. Thl-type Osp A 
specific T cells, which could lend support to the above theory. 
Although transfer of IL-4 producing Osp A-specific T cells did not 
have any beneficial effect on the host during the first 2 weeks of infection, 
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they did appear to have significant effect on the resolution phase of 
disease. In the Group III mice, those receiving Osp A-specific T cells had 
substantially less severe arthritis than those receiving Ova-specific T cells 
(severity index 1.8 vs 3.0 (P=0.005)). This is consistent with the notion 
that cytokines secreted by Th2 cells oppose the action of gamma- 
interferon on macrophages and suppress the production of gamma- 
interferon by Thl cells, thereby accelerating the resolution of 
inflammation ("disease") (59). 
The differentiation of ThO and Thl cells into Th2 cells is due, in 
part, to the antigen dose. In leishmania infection, when the antigen level 
is decreased by the effects of the Thl response in the first phase of 
infection, Thl or ThO cells may convert to Th2 cells which serve to 
downregulate the inflammatory response (leading to healing of leishmania 
lesions) (58). If we draw parallels between the Leishmania system and 
ours, the initial phase of the T cell reaction in our mice appears to be a 
Thl phenotype, which serves to control the spirochete infection by 
nonspecific immune mechanisms including macrophage activation. 
However, as the spirochetal load decreases, disease regression occurs, in 
part, because the naturally arising ThO cells may convert now more readily 
to a Th2 phenotype and secrete cytokines which will promote terminal 
differentiation of Thl cells into a Th2 phenotype. Thus, when the Osp A- 
specific Th0/Th2 cells are transferred at this phase of infection, the ThO 
cells could conceivably differentiate into Th2, and the combined effects of 
lower spirochetal load and cytokines elaborated by Th2 cells would be to 
accelerate the resolution phase of disease. 
The effects of the Osp A-specific T cells at all stages of infection 
appear to be independent of antibody, as none of the mice had detectable 
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serum levels of Osp A antibodies. In addition, minimal differences could 
be seen in the degree of heart inflammation, suggesting that the role of 
Osp A in disease in this organ may be different than disease in the joints. 
This is particularly interesting because carditis in CD4+ "knock-out" mice, 
which have no CD4+ T cells, is essentially unchanged from that seen in the 
immunologically intact littermate (60). If Osp A-specific T cells have a role 
in disease (either exacerbation or attenuation), then it is most readily 
demonstrated in arthritis. In humans, the finding of higher titer Osp A 
antibodies and greater numbers of peripheral T cells reacting with Osp A 
in patients with chronic, treatment-resistant Lyme arthritis has led to the 
speculation that persistent disease may be due to molecular mimicry 
between Osp A and joint tissue, leading to an autoreactive phenomenon 
(56). An alternative view is that these patients, because of their genetic 
background, may effectively lower their spirochetal loads by the Thl 
response and/or not readily convert to a Th2 phenotype, resulting in a 
persistent inflammatory response. 
In summary, although the numbers of mice used were small, the 
experimental data suggest that IL-4 producing Osp A-primed T cells 
transferred into B. burgdorferi infected mice do not appreciably affect the 
course of Lyme borreliosis early in disease, but accelerate the resolution of 
disease once it is established. The attenuation is possibly due to T cell 
production of cytokines that downregulate the inflammatory response at 
the time when the antigen load has reached a critical lower threshold 
which favors the development of Th2 cells in the host. Our results do not 
implicate a critical role for Osp A-specific antibodies in this process. 
Future experiments will be designed to map the cytokine environment 
during the first four weeks of infection and to determine whether 
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terminally differentiated Osp A-specific Th2 cells can help regulate 
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